NCT04637009 2024-08-02A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsAstex Pharmaceuticals, Inc.Phase 1 Terminated20 enrolled
NCT05328102 2024-04-30Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)Xencor, Inc.Phase 2 Terminated3 enrolled 6 charts
NCT01236352 2019-07-31Multiple Ascending Dose of BMS-911543Bristol-Myers SquibbPhase 1/2 Terminated98 enrolled 20 charts